Anti-CRISPR compounds and methods of use

A method, comprising:

• a) providing:
• i) a biological cell comprising at least one suspect gene;
• ii) a Type II-C Cas9/sgRNA complex wherein said Type II-C Cas9 comprises a binding site;
• and
• iii) an anti-CRISPR (Acr) protein expressed from a plasmid, said plasmid comprising a native phage-encoded Acr open reading frame gene sequence, wherein said Acr protein is capable of binding with specific affinity to said binding site;
• b) contacting said Type II-C Cas9/sgRNA complex with said biological cell such that said Type II-C Cas9/sgRNA complex hybridizes to a target site;
• c) editing said suspect gene with said Type II-C Cas9/sgRNA complex;
• and
• d) contacting said binding site with said Acr protein such that said editing is reduced,
• wherein said Acr protein is selected from the group consisting of AcrIIC1Bo having the sequence of SEQ ID NO:
• 2), AcrIICIBoe having the sequence of SEQ ID NO:
• 27, AcrIIC1Nme having the sequence of SEQ ID NO:
• 4, AcrIIC2Nme having the sequence of SEQ ID NO:
• 6, AcrIIC3Nme having the sequence of SEQ ID NO:
• 8, AcrIIC4Nme having the sequence of SEQ ID NO:
• 10;
• AcrIIC5Nme having the sequence of SEQ ID NO:
• 12, Acr6Rs having the sequence of SEQ ID NO:
• 14, and Acr7 Pa having the sequence of SEQ ID NO:
• 16.